Based on these results, we speculate that PI3K/AKT signaling inhibitors may be effective at inhibiting tumor development in ESCC patients with high IKBIP expression but may be ineffective at preventing tumor development in ESCC patients with low IKBIP expression. This evidence concerns the gene IKBIP and esophageal squamous cell carcinoma.